Nelfinavir mesylate. Antiviral for AIDS, HIV-1 protease inhibitor

Drugs of the Future

Volumn 22, Issue 4, 1997, Pages 371-377

  Rabasseda, X ^a   Martel, A M ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; STAVUDINE; TERFENADINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; VIRUS REPLICATION;

EID: 0030796614     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dressman, B.A., Fritz, J.E., Hammond, M. et al. (Agouron Pharm., Inc.). HIV protease inhibitors. JP 97501443, US 5484926, WO 9509843.
2. Jungheim, L.N., Shepherd, T.A. (Eli Lilly and Co.). Intermediate and process for making. WO 9521164.
3. Carpenter, C.C.J., Fischl, M.A., Hammer, S.M. et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA-J Amer Med Assoc 1996, 276: 146-54.
4. Deeks, S.G., Smith, M., Holodniy, M., Kahn, J.O. HIV-1 protease inhibitors. A review for clinicians. JAMA-J Amer Med Assoc 1997, 277: 145-53.
5. Kaldor, S.W., Kalish, V., Dressman, B.A. et al. Design and synthesis of potent, orally bioavailable HIV-1 protease inhibitors. 208th ACS Natl Meet (Aug 21-25, Washington DC) 1994, Abst MEDI 17.
6. Kalish, V., Kaldor, S., Shetty, B. et al. Iterative protein structure-based drug design and synthesis of HIV protease inhibitors. 13th Int Symp Med Chem (Sept 19-23, Paris) 1994, Abst ML8.
7. Tatlock, J.H., Kalish, V.J., Davies, J., Appelt, K., Reich, S., Musick, L., Wu, B., Kaldor, S. Protein structure-based drug design and synthesis of nonpeptidic HIV protease inhibitors. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst MEDI 120.
8. Kaldor, S.W., Dressman, B.A., Hammond, M. et al. Novel inhibitors of HIV-1 protease containing an isophthalic carboxamide at the P2 site. 209th ACS Natl Meet (April 2-6, Anaheim) 1995, Abst MEDI 122.
9. Varney, M.D. Progress in the development of AG-1343, a novel, potent, orally bioavailable HIV protease inhibitor. 211th ACS Natl Meet (March 24-28, New Orleans) 1996. Abst MEDI 254.
10. Shetty, B., Kaldor, S., Kalish, V., Reich, S., Webber, S. AG1343, an orally bioavailable non-peptidic HIV-1 protease inhibitor. 10th Int Conf AIDS/Int Conf STD (Aug 7-12, Yokohama) 1994, Abst 321A.
11. Webber, S., Khalil, D., Kosa, M., Patick, A., Shetty, B. Preclinical toxicokinetic studies with AG1343, an orally bioavailable HIV-1 protease inhibitor. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 93.
12. Patick, A. K., Mo, H., Markowitz, M. et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40: 292-7.
13. Shetty, B.V., Kosa, M.B., Khalil, D.A., Webber, S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996, 40: 110-4.
14. Quart, B.D., Chapman, S.K., Peterkin, J., Webber, S., Oliver, S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 - A novel HIV protease inhibitor. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst LB3.
15. Kerr, B.M., Yuen, G.J., Sandoval, T., Wu, E., Shetty, B.V., Anderson, R. The pharmacokinetics (PK) of nelfinavir (N) administered alone and with ketoconazole (K) in healthy volunteers. Clin Pharmacol Ther 1997, 61(2): Abst PI-42.
16. Yuen, G.J., Anderson, R., Sandoval, T., Wu, E., Shetty, B.V., Kerr, B.M. The pharmacokinetics (PK) of nelfinavir (N) administered alone and with rifampin (RIF) in healthy volunteers. Clin Pharmacol Ther 1997, 61 (2): Abst PI-40.
17. Kerr, B., Yuen, G., Daniels, R., Quart, B., Anderson, R. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
18. Yuen, G., Anderson, R., Daniels, R., Kerr, B. Investigations of nelfinavir mesylate (NFV) pharmacokinetic (PK) interactions with indinavir(IDV) and ritonavir (RTV). 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
19. Wu, E.Y. Sandoval, T.M., Lee, C.A., Zhang, K., Liang, B.H., Shetty, B.V. In vitro metabolism studies with the HIV-1 protease inhibitor, Viracept™ (AG1343). 7th North Amer ISSX Meet (Oct 20-24, San Diego) 1996, Abst 326.
20. Roy, S.D., Longer, M., Tsai, W.-C., Tyle, P. Aqueous solubility and dissolution behavior of nelfinavir mesylate (Viracept™), a novel HIV protease inhibitor. Pharm Res 1996, 13(9, Suppl.): Abst PDD 7119.
21. Zamansky, I., Tyle, P., Albizati, K., Wilke, T.L., Culp, G., Longer, M. Kinetics and mechanism of solution and solid state degradation for a novel HIV protease inhibitor, AG1343. Pharm Res 1995, 12(9, Suppl.): Abst PDD 7031.
22. Longer, M., Shetty, B., Zamansky, I., Tyle, P. Preformulation studies of a novel HIV protease inhibitor, AG1343. J Pharm Sci 1995, 84: 1090-3.
23. Longer, M., Wilke, T., Tyle, P., Sunami, M., Uemoto, Y., Sugimori, K. Formulation development and evaluation of Viracept™ (nelfinavir mesylate) tablets. Pharm Res 1996, 13(9, Suppl.): Abst PDD 7468.
24. Moyle, G., Youle, M., Chapman, S. et al. A phase I/II dose escalation study of the novel HIV protease inhibitor AG1343. 5th Eur Conf Clin Aspects Treat HIV Infect (Sept 26-29, Copenhagen) 1995, Abst 42.
25. Moyle, G.J., Youle, M., Higgs, C., Monaghan, J., Peterkin, J., Chapman, S., Nelson, M. Extended follow-up of safety and activity of Agouron's HIV proteinase inhibitor AG1343 (Viracept®) in virological responders from the UK phase I/II dose finding study. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.173.
26. Gathe, J. Jr., Burkhardt, B., Hawley, P., Conant, M., Peterkin, J., Chapman, S. A randomized phase II study of Viracept™, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.413.
27. Conant, M., Markowitz, M., Hurley, A., Ho, D., Peterkin, J., Chapman, S. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept™ as monotherapy in HIV positive patients. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Tu.B.2129.
28. Pedneault, L., Elion, R., Adler, M., Anderson, R., Kelleher, T., Knupp, C., Kaul, S., Kerr, B., Cross, A., Dunkle, L. Stavudine (d4T), didanosine (ddl), and nelfinavir combination therapy in HIV-infected subjects: Antiviral effect and safety in an ongoing pilot study. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
29. Markowitz, M., Cao, Y., Hurley, A. et al. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1. 11th Int Cong AIDS (July 7-12, Vancouver) 1996, Abst LB.B.6031.
30. FDA clears Agouron to market Viracept - A new HIV protease inhibitor for adults and children. Viracept to be available to patients within days. Agouron Pharmaceuticals, Inc. Press Release 1997, March 14.
31. Henry, K., Lamarca, A., Myers, R., Chapman, S. The safety of Viracept™ (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
32. Powderly, W., Sension, M., Conant, M., Stein, A., Clendeninn, N. The efficacy of Viracept™ (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.
33. Viracept combination therapy drops HIV below quantifiable levels in both blood and lymph tissue. Agouron Pharmaceuticals, Inc. Press Release 1997, April 11.
34. Markowitz, M., Winslow, D., Cao, Y. et al. Triple therapy with nelfinavir (Viracept®) in combination with AZT and 3TC in 12 antiretroviral-naive subjects chronically infected with HIV-1. 10th Int Conf Antivir Res (April 6-11, Atlanta) 1997, Late Breaker Presentation.
35. Agouron Pharmaceuticals Company Communication, March 17, 1997.